Abstract: The present invention relates to methods for assessing one's risk for suffering from severe COVID or long COVID symptoms. Also provided are methods for reducing the risk of developing severe COVID and/or long COVID symptoms.

Abstract: The present invention resides in the discovery that altered abundance of fungal species in the gut and feces of both fecal microbiota transplantation (FMT) donors and recipients may influence the outcome of FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donor or recipients for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: Methods are provided for treating metabolic diseases by way of modulating recipients' gastrointestinal tract microorganism profile such as by fecal microbiota transplantation (FMT) treatment. Also provided are methods for assessing a patient's risk of developing obesity and/or related metabolic diseases. Further provided are kits and compositions for use in these methods.

Abstract: Provided are methods for treating symptoms of autism spectrum disorder (ASD) in a human child. Methods for determining risk for A SD in human children, methods for assessing developmental age of children and for treating children in need thereof, kits and compositions for use in these methods are also provided.

Abstract: Methods and compositions for treating and/or preventing a bacterial infection in a subject are provided, in which the subject is administered a fecal sample obtained from a donor subject via fecal microbiota transplantation (FMT). The fecal sample contains bacteriophages that target the bacteria causing the infection. In some embodiments, the fecal sample containing the bacteriophages can be obtained from a donor subject who previously had the same infection but is now cured.

Abstract: A probiotic composition comprising Bifidobacterium bifidum and Bifidobacterium longum, and may further comprising Bifidobacterium adolescentis and Lactobacillus rhamnosus is provided. A prebiotic composition comprising xylooligosaccharide, galactooligosaccharide, and corn dietary fiber, and a dietary composition comprising the probiotic composition and the prebiotic composition are provided. Use of the foregoing compositions in the preparation of a dietary product or a drug for assisting in preventing and/or treating a pathogen infection of an individual, enhancing the therapeutic effect of a pathogen infection of an individual, improving the immunity of an individual, or balancing the gut microecology of an individual is provided. The foregoing compositions can be used in patients suffering from COVID-19.

Abstract: Methods are provided for treating COVID-19 patients to facilitate their recovery from the disease as well as for prognosis of severity of COVID-19 among patients who have been infected by SARS-CoV-2. Also provided are kits and compositions for use in these methods.

Abstract: The present invention provides for compositions and methods for treating long COVID symptoms or reducing the risk of developing such symptoms.

Abstract: Certain microorganism species in a composition for use in fecal microbiota transplantation (FMT), including fecal material obtained from an FMT donor, can affect the outcome of FMT treatment such as regulating the bodyweight and cholesterol level in FMT recipients. Thus, methods are provided for identifying subjects as suitable donor to optimize FMT outcome and for pretreating donors and/or recipients for optimized FMT outcome. Also provided are kits and compositions for improving FMT outcome, including for bodyweight and/or cholesterol reduction.

Abstract: The present invention resides in the discovery that abundance and diversity of viral species in the fecal matter from a donor used in fecal microbiota transplantation (FMT) treatment can influence the outcome of the FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donors for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: Methods are provided for identifying subjects as suitable donor or recipients for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: The present invention resides in the discovery that abundance and diversity of viral species in the fecal matter from a donor used in fecal microbiota transplantation (FMT) treatment can influence the outcome of the FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donors for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.